Results 51 to 60 of about 99,547,245 (298)

Supplementary Figure S6: Ipilimumab does not deplete CD4+CTLA-4+FOXP3+ Tregs from Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers

open access: yes, 2019
Tumor infiltrating cells from paired melanoma tissue (N=5 pre-Ipi; N=5 post-Ipi) were analyzed by CyTOF. The impact of ipilimumab on the intratumoral frequency of A) CD3+CD4+FOXP3+CTLA-4+ (Tregs), B) CD3+CD4+FOXP3-CTLA-4+ T cells, and C) CD3+CD4+FOXP3 ...
Padmanee Sharma (8133285)   +8 more
core   +1 more source

Supplementary Data from Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs

open access: yes, 2022
Supplementary Data from Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited ...
Andrew Sharabi (3158010)   +15 more
core   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

open access: yesMolecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira   +7 more
wiley   +1 more source

CTLA-4: Not All Costimulation Is Stimulatory [PDF]

open access: yesThe Journal of Immunology, 2011
To activate a T cell, it was widely accepted, even in the 1960s, that there had to be a “signal one,” namely, receptor recognition of a foreign Ag. That fact did not make it less exciting when, in the early 1980s, Abs to the TCR were generated and the genes that encode it identified ([1][1 ...
Hugh, Auchincloss, Laurence A, Turka
openaire   +2 more sources

Supplementary Figures 1 - 4 from Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

open access: yes, 2013
PDF file - 206K, Supplemental Figure S1. Equivalent binding of anti-CTLA-4 isotypes to cell surface CTLA-4. Supplemental Figure S2. Serum concentrations of anti-CTLA-4 isotypes in C57BL/6 mice. Supplemental Figure S3.
Mark J. Selby (3110964)   +6 more
core   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

open access: yesMolecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David   +12 more
wiley   +1 more source

Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies

open access: yesFrontiers in Pediatrics, 2021
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a crucial immune checkpoint that is constitutively expressed in regulatory T (Treg) cells. Following T-cell activation, CTLA-4 is rapidly mobilized from its intracellular vesicle pool to the cell surface to ...
Laura Gámez-Díaz   +2 more
doaj   +1 more source

In vitro generation of regulatory T cells: A challenging tool for studying immune aging in humans

open access: yesFEBS Open Bio, EarlyView.
In vitro induction of human regulatory T cells using standard protocols generates suppressive, Foxp3‐expressing CD4+ T cells independently of TGF‐β supplementation and donor age. Regulatory T (Treg) cells play a key role in immune tolerance and homeostasis.
Lynn Muller   +3 more
wiley   +1 more source

Polymorphic sites at the immunoregulatory CTLA-4 gene are associated with chronic chagas disease and its clinical manifestations. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND:Chagas disease affects approximately 10 million people mainly in Latin America. The immune regulation by the host seems to be an essential factor for disease evolution, and immune system inhibitory molecules such as CTLA-4 and PD-1 favor the ...
Fabrício C Dias   +11 more
doaj   +1 more source

CTLA-4: From conflict to clinic [PDF]

open access: yesThe Journal of Experimental Medicine, 2007
CTLA-4 was first identified in 1991 as a second receptor for the T cell costimulation ligand B7. Uncertainties about its biological function plagued the early years after its discovery until 1995, when it was confirmed to be an inhibitor of T cell responses.
openaire   +2 more sources

Home - About - Disclaimer - Privacy